We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
Read MoreHide Full Article
For the quarter ended June 2026, Evolent Health (EVH - Free Report) reported revenue of $652.52 million, up 46.9% over the same period last year. EPS came in at $0.02, compared to -$0.10 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $611.13 million, representing a surprise of +6.77%. The company delivered an EPS surprise of +300%, with the consensus EPS estimate being -$0.01.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Average PMPM Fees / Revenue per Case - Performance Suite: $24.05 compared to the $20.99 average estimate based on two analysts.
Average PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.34 versus $0.35 estimated by two analysts on average.
Average PMPM Fees / Revenue per Case - Administrative Services: $13.46 versus $15.03 estimated by two analysts on average.
Average Lives on Platform / Cases - Cases: 12 thousand versus 11.1 thousand estimated by two analysts on average.
Average Lives on Platform / Cases - Performance Suite: 6.72 million versus 6.86 million estimated by two analysts on average.
Average Lives on Platform / Cases - Specialty Technology and Services Suite: 75.64 million compared to the 75.28 million average estimate based on two analysts.
Average Lives on Platform / Cases - Administrative Services: 1.19 million versus the two-analyst average estimate of 1.12 million.
Average PMPM Fees / Revenue per Case - Cases: $3,608.00 compared to the $3,795.59 average estimate based on two analysts.
Total Revenue by product type- Performance Suite: $484.5 million compared to the $441.89 million average estimate based on three analysts. The reported number represents a change of +80.8% year over year.
Total Revenue by product type- Cases: $41.87 million versus $41.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
Total Revenue by product type- Administrative Services: $47.99 million versus the three-analyst average estimate of $49.59 million. The reported number represents a year-over-year change of -14.1%.
Total Revenue by product type- Specialty Technology and Services Suite: $78.16 million versus $80.06 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -4% change.
Shares of Evolent Health have returned -45% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
View the Zacks #1 Rank List
Image: Bigstock
Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics
For the quarter ended June 2026, Evolent Health (EVH - Free Report) reported revenue of $652.52 million, up 46.9% over the same period last year. EPS came in at $0.02, compared to -$0.10 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $611.13 million, representing a surprise of +6.77%. The company delivered an EPS surprise of +300%, with the consensus EPS estimate being -$0.01.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Evolent Health here>>>
Shares of Evolent Health have returned -45% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.